Skip to content

Friday, July 11, 2025

Latest:

Dr. Wylie W. Vale, Jr. Memorial Lecture celebrates and inspires research
Michael E. DeBakey Department of Surgery Research Day
Healthy Habits: Dr. Roy Williams Jr. starts his day with exercise
Surviving cancer and tracheoesophageal fistula: Sandy Tovey’s journey
Handy ‘MasSpec Pen’ collection could help detect opioids from the skin

Home
Momentum
From The Labs
- About From the Labs
- Follow From The Labs on Twitter
Policywise
- About PolicyWise
- Follow @BCMEthics on Twitter
The Stitch
- About The Stitch
Progress Notes
bcm.edu

CDK4/6 inhibitor therapy

Interferon linked to ER+/HER- metastatic breast cancer resistance to therapy

March 12, 2021 CDK4/6 inhibitor therapy, endocrine therapy, ER+/HER2- breast cancer, Interferon, Metastatic breast cancer, Research, resistance to cancr treatment

Both preclinical models and tumor samples from patients with ER+/HER2- breast cancer link high IFN signaling to resistance to treatment.

From the Labs: Image of the Month

From the Labs: a closer look at metastatic medulloblastoma

Healthy Habits: A DOC-umentary Series

Archives

Archives

Search

©1998 - 2023 Baylor College of Medicine®
One Baylor Plaza, Houston, Texas 77030
(713) 798-4951